MaxCyte (MXCT) Q2 Revenue Drops 18%

MaxCyte (NASDAQ:MXCT), a cell engineering and biotechnology platform provider, reported its second quarter 2025 results on August 6, 2025. The most important news was an 18% year-over-year decline in total revenue (GAAP) and a downward revision of its full-year outlook. Revenue (GAAP) was $8.5 million, underperforming analyst expectations by about $1.1 million (GAAP), while GAAP net losses widened compared to the prior-year period. Earnings per share (EPS) (GAAP) matched forecasts, but the company cited continued lumpiness in its high-margin SPL revenue. Overall, core business revenue grew, but also highlighted ongoing challenges in realizing consistent top-line growth and operational leverage, as evidenced by an 18% decrease in total revenue (GAAP) compared to Q2 2024. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. MaxCyte (NASDAQ:MXCT) develops and sells cell engineering technology used primarily for cell and gene therapies. Its proprietary Flow Electroporation technology powers the ExPERT platform, which enables the efficient transfer of molecules into different cell types -- a crucial step in developing advanced therapies.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool